Key result
Myocardial ischemia-reperfusion injury is upregulated by angiotensin II, leading to increased infarct size, which can be reduced by ACE inhibitors, ACE2 activators, and angiotensin II antagonists.
Why the study?
Do ACE inhibitors, ACE2 activators, and angiotensin II antagonists reduce myocardial ischemia-reperfusion injury?
Do ACE inhibitors, ACE2 activators, and angiotensin II antagonists reduce myocardial ischemia-reperfusion injury?
Pharmacological modulation of the cardiac renin-angiotensin system using ACE inhibitors, ACE2 activators, or angiotensin II antagonists represents a promising strategy to attenuate myocardial ischemia-reperfusion injury.
Cardio-vascular diseases are the leading cause of morbidity and mortality. Ischemia is a state of oxygen deprivation in tissues, whereas reperfusion is restoration of blood flow in ischemic tissues. Myocardial damage of tissue during reperfusion after ischemic insult is known as myocardial ischemia-reperfusion (I/R) injury. It induces damage to cardiac muscle via increasing expression of oxygen, sodium and calcium ions which are responsible in the activation of proteases and cell death. Heart renin angiotensin system (RAS) plays an important role in the myocardial ischemia and reperfusion injury. Angiotensin (1-7) is responsible for vasodilation and angiotensin II for vasoconstriction. Here-in we reviewed how myocardial I/R injury sets in by up-regulation of angiotensin II that leads to increased infarct size, which can be reduced by the use of ACE inhibitors, ACE2 activators and angiotensin II antagonist.
No takes yet. Share an insight, caveat, or question.
Agrawal et al. (2016) conducted a review in Myocardial ischemia-reperfusion injury. ACE inhibitors, ACE2 activators, and angiotensin II antagonists was evaluated. Myocardial ischemia-reperfusion injury is upregulated by angiotensin II, leading to increased infarct size, which can be reduced by ACE inhibitors, ACE2 activators, and angiotensin II antagonists.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: